Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. (Q39138428)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 November 2016

Language	Label	Description	Also known as
English	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.	scientific article published on 28 November 2016

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

phase II clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

ovarian carcinoma

1 reference

based on heuristic

inferred from title

Scott H Kaufmann

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Alexandra Leary

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

31

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

James D Brenton

14

object named as

James D Brenton

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Isabelle Ray-Coquard

17

object named as

Isabelle Ray-Coquard

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

author name string

Elizabeth M Swisher

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Kevin K Lin

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Amit M Oza

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Clare L Scott

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Heidi Giordano

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

James Sun

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Gottfried E Konecny

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Robert L Coleman

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Anna V Tinker

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

David M O'Malley

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Rebecca S Kristeleit

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Ling Ma

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Katherine M Bell-McGuinn

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Janiel M Cragun

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Ana Oaknin

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Maria I Harrell

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Elaina Mann

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Anne Floquet

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Thomas C Harding

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Sandra Goble

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Lara Maloney

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Jeff Isaacson

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Andrew R Allen

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Lindsey Rolfe

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Roman Yelensky

29

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Mitch Raponi

30

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

publication date

29 November 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

75-87

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrated genomic analyses of ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The medical dictionary for regulatory activities (MedDRA).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Whole-genome characterization of chemoresistant ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrative clinical genomics of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930559-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)30559-9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908594%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39138428&oldid=1790286343"